Endomorphins interact with tachykinin receptors.
Soon after the discovery of endomorphins several studies indicated differences between pharmacological effects of endomorphins and other MOR selective ligands, as well as differences between the effects of endomorphin I and endomorphin II. We now propose that these differences are the result of an additional non-opioid property of endomorphins, namely, their weak antagonist properties with respect to tachykinin NK1 and NK1 receptors.
Kosson
Piotr
P
Medical Research Centre, Polish Academy of Sciences, 02106 Warsaw, Poland.
Bonney
Iwona
I
Carr
Daniel B
DB
Lipkowski
Andrzej W
AW
D000818:Animals; D001667:Binding, Competitive; D016466:CHO Cells; D002462:Cell Membrane / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D006168:Guinea Pigs; D006801:Humans; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D015394:Molecular Structure; D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D011869:Radioligand Assay; D018040:Receptors, Neurokinin-1 / Q000235:genetics / Q000378:metabolism; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D018042:Receptors, Neurokinin-3 / Q000235:genetics / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013373:Substance P / Q000494:pharmacology
D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides; D010446:Peptide Fragments; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D011957:Receptors, Opioid; D018039:Receptors, Tachykinin; C105293:endomorphin 1; D013373:Substance P; C105294:endomorphin 2; C061335:substance P (7-11)